Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 3/2002

01-09-2002 | Original Article

Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) using a single intravenous dose schedule

Authors: Lynn Feun, Manuel Modiano, King Lee, John Mao, Angela Marini, Niramol Savaraj, Patricia Plezia, Bijan Almassian, Elizabeth Colacino, Jessica Fischer, Susan MacDonald

Published in: Cancer Chemotherapy and Pharmacology | Issue 3/2002

Login to get access
Metadata
Title
Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) using a single intravenous dose schedule
Authors
Lynn Feun
Manuel Modiano
King Lee
John Mao
Angela Marini
Niramol Savaraj
Patricia Plezia
Bijan Almassian
Elizabeth Colacino
Jessica Fischer
Susan MacDonald
Publication date
01-09-2002
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 3/2002
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-002-0480-0

Other articles of this Issue 3/2002

Cancer Chemotherapy and Pharmacology 3/2002 Go to the issue

Original Article

A formula for predicting optimal dosage of nedaplatin based on renal function in adult cancer patients

Original Article

Recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein Enbrel in patients with refractory hematologic malignancies

Short Communication

Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin

Original Article

Mechanisms of the apoptotic activity of Cl-F-araA in a human T-ALL cell line, CCRF-CEM

Original Article

Phase I and pharmacokinetic study of vinblastine and high-dose megestrol acetate

Original Article

Potentiation of the antitumour effect of cyclophosphamide in mice by thalidomide
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits